307 related articles for article (PubMed ID: 14668693)
1. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Kane SV; Bjorkman DJ
Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
[TBL] [Abstract][Full Text] [Related]
2. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
3. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
4. Review article: balsalazide therapy in ulcerative colitis.
Ragunath K; Williams JG
Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
[TBL] [Abstract][Full Text] [Related]
5. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
Nikfar S; Rahimi R; Rezaie A; Abdollahi M
Dig Dis Sci; 2009 Jun; 54(6):1157-70. PubMed ID: 18770034
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
8. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Sutherland L; Macdonald JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD000544. PubMed ID: 16625537
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Loftus EV; Kane SV; Bjorkman D
Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
[TBL] [Abstract][Full Text] [Related]
11. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Muijsers RB; Goa KL
Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
[TBL] [Abstract][Full Text] [Related]
12. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Sutherland L; Roth D; Beck P; May G; Makiyama K
Cochrane Database Syst Rev; 2002; (4):CD000544. PubMed ID: 12519547
[TBL] [Abstract][Full Text] [Related]
13. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
Hanauer SB
Am J Gastroenterol; 2003 Mar; 98(3):697-8. PubMed ID: 12650813
[No Abstract] [Full Text] [Related]
14. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.
Hanauer SB
Gut; 1999 Apr; 44(4):455. PubMed ID: 10075949
[No Abstract] [Full Text] [Related]
15. The mesalamine wars heat up-enter balsalazide.
Cohen RD
Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
[No Abstract] [Full Text] [Related]
16. Will the real 5-aminosalicylic acid please stand up?
Regueiro MD
Inflamm Bowel Dis; 1999 May; 5(2):147-8. PubMed ID: 10338387
[No Abstract] [Full Text] [Related]
17. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
18. Balsalazide.
Prakash A; Spencer CM
Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
[TBL] [Abstract][Full Text] [Related]
19. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Baker DE; Kane S
Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
